See termination reason in detailed description.

The purpose of this study is to explore the safety, toleration and dose response of PHA-794428 after multiple weekly injections in male and female growth hormone deficient patients.

The study terminated on 10-Dec-2007. Pfizer's decision to terminate the program was due to cases of injection-site lipoatrophy that were reported in the clinical Phase 2 studies after a single injection of PHA 794428.

Inclusion Criteria:

• Male and female patients with severe AGHD.
• Hypopituitary patients must be on adequate hormone replacement therapy for at least 6 months.

Exclusion Criteria:

• AGHD patients with uncontrolled pituitary tumor growth.
• Tumors within 3 mm of the optic chiasm.
• Patients with diabetes mellitus.